FIG 2.
Consort diagram of patients with combined loss of heterozygosity of chromosomes 1p and 16q (LOH1p/16q). FHWT, favorable histology Wilms tumor; LOH, loss of heterozygosity; NWTS-5, National Wilms Tumor Study 5; regimen DD4A, vincristine, dactinomycin, and doxorubicin with no radiation therapy; regimen EE4A, vincristine and dactinomycin; regimen M: vincristine, dactinomycin, and doxorubicin alternating with cyclophosphamide and etoposide with radiation therapy.